2910 related articles for article (PubMed ID: 32454513)
1. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
[TBL] [Abstract][Full Text] [Related]
2. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Shi R; Shan C; Duan X; Chen Z; Liu P; Song J; Song T; Bi X; Han C; Wu L; Gao G; Hu X; Zhang Y; Tong Z; Huang W; Liu WJ; Wu G; Zhang B; Wang L; Qi J; Feng H; Wang FS; Wang Q; Gao GF; Yuan Z; Yan J
Nature; 2020 Aug; 584(7819):120-124. PubMed ID: 32454512
[TBL] [Abstract][Full Text] [Related]
3. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
4. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
[TBL] [Abstract][Full Text] [Related]
5. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
[TBL] [Abstract][Full Text] [Related]
6. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
7. Potently neutralizing and protective human antibodies against SARS-CoV-2.
Zost SJ; Gilchuk P; Case JB; Binshtein E; Chen RE; Nkolola JP; Schäfer A; Reidy JX; Trivette A; Nargi RS; Sutton RE; Suryadevara N; Martinez DR; Williamson LE; Chen EC; Jones T; Day S; Myers L; Hassan AO; Kafai NM; Winkler ES; Fox JM; Shrihari S; Mueller BK; Meiler J; Chandrashekar A; Mercado NB; Steinhardt JJ; Ren K; Loo YM; Kallewaard NL; McCune BT; Keeler SP; Holtzman MJ; Barouch DH; Gralinski LE; Baric RS; Thackray LB; Diamond MS; Carnahan RH; Crowe JE
Nature; 2020 Aug; 584(7821):443-449. PubMed ID: 32668443
[TBL] [Abstract][Full Text] [Related]
8. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI
Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135
[TBL] [Abstract][Full Text] [Related]
10. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
11. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
Tai W; Zhang X; He Y; Jiang S; Du L
Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117
[TBL] [Abstract][Full Text] [Related]
12. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
Yu F; Xiang R; Deng X; Wang L; Yu Z; Tian S; Liang R; Li Y; Ying T; Jiang S
Signal Transduct Target Ther; 2020 Sep; 5(1):212. PubMed ID: 32963228
[TBL] [Abstract][Full Text] [Related]
13. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
Qi X; Ke B; Feng Q; Yang D; Lian Q; Li Z; Lu L; Ke C; Liu Z; Liao G
Chem Commun (Camb); 2020 Aug; 56(61):8683-8686. PubMed ID: 32613971
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.
Hurlburt NK; Seydoux E; Wan YH; Edara VV; Stuart AB; Feng J; Suthar MS; McGuire AT; Stamatatos L; Pancera M
Nat Commun; 2020 Oct; 11(1):5413. PubMed ID: 33110068
[TBL] [Abstract][Full Text] [Related]
15. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
[TBL] [Abstract][Full Text] [Related]
16. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
17. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
Papageorgiou AC; Mohsin I
Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
[TBL] [Abstract][Full Text] [Related]
18. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
[TBL] [Abstract][Full Text] [Related]
20. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
